Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03234400 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings
A Phase 1 study, sponsored by International Partnership for Microbicides.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT03234400 is a Phase 1 study that has completed, run by International Partnership for Microbicides. The registered enrollment target is 49 participants.
The verdict
NCT03234400, a Phase 1 study, has completed, sponsored by International Partnership for Microbicides.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
Participants will be randomized to one of three study vaginal rings (VRs) in a 1:1:1 ratio, 25 mg, 100 mg or 200 mg VRs.
Interventions
- COMBINATION_PRODUCT Dapivirine Vaginal Ring, 25 mg
- COMBINATION_PRODUCT Dapivirine Vaginal Ring, 100 mg
- COMBINATION_PRODUCT Dapivirine Vaginal Ring, 200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2017-12-04 |
| Est. Completion | 2019-01-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03234400
The ClinicalTrials.gov registry entry for NCT03234400 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International Partnership for Microbicides, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dapivirine Vaginal Ring, 25 mg is the first listed.
NCT03234400 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03234400 about?
NCT03234400 is a clinical study titled "A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings". Participants will be randomized to one of three study vaginal rings (VRs) in a 1:1:1 ratio, 25 mg, 100 mg or 200 mg VRs.
What is the current status of trial NCT03234400?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2017-12-04. Estimated completion is 2019-01-23.
What interventions are being tested in trial NCT03234400?
The interventions under investigation include: Dapivirine Vaginal Ring, 25 mg (COMBINATION_PRODUCT), Dapivirine Vaginal Ring, 100 mg (COMBINATION_PRODUCT), Dapivirine Vaginal Ring, 200 mg (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03234400?
This trial is sponsored by International Partnership for Microbicides, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.